Manufactures specialty pharmaceutical intermediates, mainly for contrast media (imaging agents) and high-intensity sweeteners.
Manufactures specialty pharmaceutical intermediates, mainly for contrast media (imaging agents) and high-intensity sweeteners.
Supplies intermediates, the chemical building blocks, to a small group of global contrast-media makers under long relationships, so sales rest on a few buyers and on their production plans. Saccharin and custom-synthesis work add variety, and contrast-media volumes follow imaging procedures worldwide.
In one line: A niche pharma-intermediate/specialty-chemical maker.
Moat: narrow (process know-how, customer qualification). Specialized iodine chemistry and long-qualified supply relationships with global contrast media makers.
Headquarters: Mumbai, India · Founded: 1968 · Employees: 581
Size Blue Jet Healthcare (BLUEJET.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.05B, the 583rd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹518.45 on 18 Nov 2026.
Performance Over six months the shares gained 18.6%, against -10.6% for the median peer and +3.8% for the India market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue fell 7.0% over the last twelve months (peer median +3.1%); the operating margin is 28.2% (peer median 8.7%).
Valuation It trades at 30.6× forward earnings against a peer median of 14.5× (2nd most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 41% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +27 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.5 points below its cost of capital (18.9% WACC).
Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹11.0B | ₹9.42B | ₹10.2B | ₹7.08B | ₹7.18B |
| Revenue growth | — | -8% | +45% | -1% | — |
| Gross profit | ₹4.66B | ₹3.62B | ₹4.41B | ₹2.77B | ₹2.70B |
| EBITDA | ₹3.35B | ₹2.96B | ₹3.79B | ₹2.35B | ₹2.21B |
| Net income | ₹2.85B | ₹2.48B | ₹3.05B | ₹1.64B | ₹1.60B |
| Free cash flow | n/a | ₹1.19B | -₹289M | ₹674M | ₹823M |
| Capital expenditure | n/a | ₹2.19B | ₹799M | ₹1.74B | ₹593M |
| Total debt | ₹385M | ₹437M | ₹215M | ₹31.1M | ₹49.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Blue Jet Healthcare BLUEJET.NS | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% |
| Neuland Laboratories NEULANDLAB.NS | $2.95B | +28% | +50% | 26% | 63.4× | n/a |
| Divi's Laboratories DIVISLAB.NS | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BLUEJET.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.2% | -5.9% | 4th highest of 21 |
| 6-month return | +18.6% | -10.6% | 5th highest of 21 |
| Distance from 52-week high | -20.0% | -32.1% | 4th highest of 21 |
| Revenue growth (TTM) | -7.0% | +3.1% | 4th lowest of 18 |
| Operating margin | 28.2% | 8.7% | highest of 19 |
| Forward P/E | 30.6× | 14.5× | 2nd most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 40.8% | 1.0% | most demanding of 14 |
| Growth delivered (Del g) | +13.8% | +6.5% | 3rd highest of 14 |
| Hurdle (Req g minus delivered) | +27.0 pp | -4.0 pp | most demanding of 14 |
| ROIC minus cost of capital | -1.5 pp | +0.2 pp | 5th lowest of 19 |
| EV / EBITDA | 26.4× | 7.3× | most expensive of 5 |
| Net debt / EBITDA | -2.9× | -1.3× | least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 23.2× | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% | +12.7% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 4.7× | -6.5% | -7.7% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% | +12.1% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 24.6× | 4.4% | +7.7% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 4.3× | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | n/a | 1.0% | -4.2% |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | n/a | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 15.5× | -3.6% | +4.2% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 18.1× | 4.9% | +11.3% |